# Phase 1 myositis trials recruiting: 24 (November 2026)

Updated November 19, 2026.

ClinicalTrials.gov lists 24 trials in phase 1 for myositis that are recruiting or not yet recruiting, as read on November 19, 2026.

## The full list

Recruiting Phase 1 myositis trials: 24 rows for $5, recruiting or not yet recruiting on ClinicalTrials.gov as read on November 19, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email.

Buy: https://specstream.ai/data/clinical-trials/recruiting/phase-1/myositis

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 24
- Recruiting or not yet: 24
- Read on: November 19, 2026

## Trials

The 24 newest of 24, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| October 14, 2026 | NCT07873931 | A Study of BMS-986553 in Participants With Refractory Autoimmune Diseases | Bristol-Myers Squibb | Phase 1 | Not yet recruiting | Systemic Lupus Erythematosus, Sjögren's Disease, Rheumatoid Arthritis, Idiopathic Inflammatory Myopathies, Systemic... | 60 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07873931) |
| July 20, 2026 | NCT07715136 | BCMA-CD19 cCAR-T for the Treatment of Refractory Inflammatory Myopathy | iCell Gene Therapeutics | Phase 1 | Recruiting | Inflammatory Myopathy | 10 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07715136) |
| April 22, 2026 | NCT07544225 | Study Investigating the Safety of Anti-CD19 CAR-T Cells Therapy Produced at Gustave Roussy for Adults With Severe and Refractory Systemic... | Gustave Roussy, Cancer Campus, Grand Paris | Phase 1 | Not yet recruiting | Rheumatoid Arthritis (RA), Systemic Lupus Erythematosus (SLE), Sjogren's Disease With Dry Eyes, Systemic Sclerosis... | 6 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07544225) |
| April 13, 2026 | NCT07526493 | Safety and Pharmacodynamics of QH103 Cell Injection in the Treatment of Patients With Relapsed/Refractory Antibody-Mediated Neurological... | Tongji Hospital | Phase 1 | Recruiting | Multiple Sclerosis (MS), Neuromyelitis Optica Spectrum Disorder (NMOSD), Autoimmune Encephalitis (AE), Chronic... | 6 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07526493) |
| February 27, 2026 | NCT07439029 | YTS109 in Pediatric Relapsed/Refractory Autoimmune Diseases | Children's Hospital of Fudan University | Phase 1 | Not yet recruiting | Systemic Lupus Erythematosus (SLE), Diffuse Systemic Sclerosis, Idiopathic Inflammatory Myopathies (IIMs), ANCA... | 12 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07439029) |
| February 17, 2026 | NCT07413341 | A Clinical Study of TI-0032-III Injection in Patients With Relapsed and Refractory Autoimmune Diseases | Therorna | Phase 1 | Recruiting | Systemic Lupus Erythematosus (SLE), Sjogren's Syndrome (SS), Systemic Sclerosis (SSc), Inflammatory Myopathy, ANCA... | 12 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07413341) |
| January 28, 2026 | NCT07371468 | A Study of GSK5926371 in Participants With B-cell Driven Autoimmune Rheumatic Diseases (ARD) | GlaxoSmithKline | Phase 1 | Recruiting | Systemic Lupus Erythematosus | 44 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07371468) |
| January 9, 2026 | NCT07331272 | A Study of LUCAR-G79D in Subjects With Relapsed/Refractory Systemic Lupus Erythematosus (r/r SLE) and Idiopathic Inflammatory Myopathies... | Nanjing Legend Biotech Co. | Phase 1 | Recruiting | Systemic Lupus Erythematosus (SLE), Idiopathic Inflammatory Myopathies(IIM) | 38 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07331272) |
| December 16, 2025 | NCT07284797 | A Phase 1 Open-label Study to Evaluate Safety in Healthy Participants and Participants With Autoimmune Diseases | Xencor, Inc. | Phase 1 | Recruiting | Healthy, Idiopathic Inflammatory Myopathies, Systemic Sclerosis, Sjögren's Disease | 60 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07284797) |
| November 19, 2025 | NCT07236801 | Exploratory Clinical Study on YTS109 Cell Therapy for Autoimmune Diseases | China Immunotech (Beijing) Biotechnology Co., Ltd. | Phase 1 | Recruiting | Systemic Lupus Erythematosus (SLE), Systemic Sclerosis, Sjogren's Syndrome (SS), Inflammatory Myopathy, Anti-Neutrophil... | 18 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07236801) |
| November 19, 2025 | NCT07236762 | An Exploratory Clinical Study of YTS109 Cell for R/R Autoimmune Diseases | China Immunotech (Beijing) Biotechnology Co., Ltd. | Phase 1 | Recruiting | Systemic Lupus Erythematosus, Lupus Nephritis (LN), Sjogren's Syndrome, Inflammatory Myopathy, Anti-Neutrophil... | 18 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07236762) |
| November 14, 2025 | NCT07229144 | OM336 in Seropositive Autoimmune Diseases | Lakefront Biotherapeutics West LLC | Phase 1 | Recruiting | Sjogrens Disease, Idiopathic Inflammatory Myopathy (IIM) | 39 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07229144) |
| August 14, 2025 | NCT07123519 | A Clinical Study of YTS109 Cells for the Treatment of R/R Autoimmune Diseases | China Immunotech (Beijing) Biotechnology Co., Ltd. | Phase 1 | Recruiting | Systemic Lupus Erythematosus (SLE), Lupus Nephritis (LN), Sjogren&#39;s Syndrome (SS), Inflammatory Myopathy... | 18 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07123519) |
| August 11, 2025 | NCT07115745 | A Study of Healthy Donor CD19-targeted Allogeneic CAR T Cells in Participants With Severe, Refractory Autoimmune Diseases | Juno Therapeutics, Inc., a Bristol-Myers Squibb Company | Phase 1 | Recruiting | Refractory Autoimmune Diseases | 125 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07115745) |
| August 5, 2025 | NCT07104721 | A Clinical Study of YTS109 Cell for R/R Autoimmune Diseases | China Immunotech (Beijing) Biotechnology Co., Ltd. | Phase 1 | Recruiting | Systemic Lupus Erythematosus (SLE), Lupus Nephritis (LN), Systemic Sclerosis (SSc), Inflammatory Myopathy... | 18 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07104721) |
| July 25, 2025 | NCT07085676 | Phase 1 Study of HBI0101 CAR-T in Refractory B-Cell Autoimmune Diseases | Sponsor not shown (see the record) | Phase 1 | Recruiting | Systemic Sclerosis (SSc), Idiopathic Inflammatory Myopathy (IIM), Rheumatoid Arthritis (RA), Systemic Lupus... | 120 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07085676) |
| July 25, 2025 | NCT07085104 | A Study to Investigate the Safety and Preliminary Efficacy of ALLO-329, an Allogeneic CAR T-cell Therapy, in Adults With Autoimmune Disease | Allogene Therapeutics | Phase 1 | Recruiting | Systemic Lupus Erythematosus (With and Without Nephritis), Idiopathic Inflammatory Myopathy, Systemic Sclerosis | 66 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07085104) |
| May 20, 2025 | NCT06980597 | A Study of OL-108 in Relapsed/Refractory Autoimmune Diseases | Beijing GoBroad Hospital | Phase 1 | Recruiting | Systemic Lupus Erythematosus (SLE), Idiopathic Inflammatory Myopathy (IIM), Systemic Sclerosis (SSc), ANCA Associated... | 44 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06980597) |
| May 18, 2025 | NCT06978738 | UCAR T-cell Therapy Targeting CD19/ BCMA in Patients With Relapse/ Refractory Autoimmune Diseases | Changzhou No.2 People's Hospital | Phase 1 | Not yet recruiting | Systemic Lupus Erythematosus, Autoimmune Hemolytic Anemia, Myasthenia Gravis, Systemic Sclerosis, ANCA-Associated... | 18 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06978738) |
| May 18, 2025 | NCT06978647 | A Clinical Study of YTS109 Cell in R/R Autoimmune Diseases | China Immunotech (Beijing) Biotechnology Co., Ltd. | Phase 1 | Recruiting | Systemic Lupus Erythematosus (SLE), Systemic Sclerosis (SSc), Inflammatory Myopathy, Anti-Neutrophil Cytoplasmic... | 12 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06978647) |
| April 23, 2025 | NCT06941129 | CAR T-cell Therapy Targeting CD19 and BCMA in Patients With Relapse/Refractory Autoimmune Diseases | Institute of Hematology & Blood Diseases Hospital, China | Phase 1 | Recruiting | Systemic Lupus Erythematosus, Systemic Sclerosis (SSc), Inflammatory Myopathy, ANCA-Associated Vasculitis (AAV)... | 12 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06941129) |
| April 13, 2025 | NCT06925542 | A Safety and Efficacy Study Evaluating CTX112 in Adult Subjects With Refractory Autoimmune Disease | CRISPR Therapeutics | Phase 1 | Recruiting | SLE (Systemic Lupus), Lupus Erythematosus, Systemic, Lupus Nephritis, Systemic Sclerosis, Inflammatory Myopathy... | 80 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06925542) |
| April 8, 2025 | NCT06916806 | A Study to Investigate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD5492 in Adult Participants With Systemic Lupus... | AstraZeneca | Phase 1 | Recruiting | Systemic Lupus Erythematosus, Idiopathic Inflammatory Myopathies, Rheumatoid Arthritis | 72 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06916806) |
| March 13, 2024 | NCT06308978 | A Phase 1 Study of FT819 in B-cell Mediated Autoimmune Disease | Fate Therapeutics | Phase 1 | Recruiting | Antineutrophilic Cytoplasmic Antibody (ANCA)- Associated Vasculitis (AAV), Idiopathic Inflammatory Myositis (IIM)... | 244 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06308978) |

## Sponsors with the most

| Sponsor | Trials |
| --- | --- |
| China Immunotech (Beijing) Biotechnology Co., Ltd. | 5 |
| iCell Gene Therapeutics | 1 |
| Changzhou No.2 People's Hospital | 1 |
| Lakefront Biotherapeutics West LLC | 1 |
| Beijing GoBroad Hospital | 1 |
| Gustave Roussy, Cancer Campus, Grand Paris | 1 |
| Institute of Hematology & Blood Diseases Hospital, China | 1 |
| Nanjing Legend Biotech Co. | 1 |
| [Bristol-Myers Squibb](https://specstream.ai/data/clinical-trials/company/bristol-myers-squibb) | 1 |
| Children's Hospital of Fudan University | 1 |
| Tongji Hospital | 1 |
| Therorna | 1 |
| Juno Therapeutics, Inc., a Bristol-Myers Squibb Company | 1 |
| [Xencor, Inc.](https://specstream.ai/data/clinical-trials/company/xencor-inc) | 1 |
| [AstraZeneca](https://specstream.ai/data/clinical-trials/company/astrazeneca) | 1 |
| Allogene Therapeutics | 1 |
| [GlaxoSmithKline](https://specstream.ai/data/clinical-trials/company/glaxosmithkline) | 1 |
| [Fate Therapeutics](https://specstream.ai/data/clinical-trials/company/fate-therapeutics) | 1 |
| CRISPR Therapeutics | 1 |

## By country

| Country | Trials |
| --- | --- |
| China | 14 |
| France | 6 |
| United States | 6 |
| Germany | 4 |
| Spain | 4 |
| Poland | 3 |
| Israel | 2 |
| Netherlands | 2 |
| Australia | 2 |
| Brazil | 2 |
| Canada | 2 |
| Japan | 2 |
| United Kingdom | 2 |
| New Zealand | 1 |
| Belgium | 1 |
| Czechia | 1 |
| Romania | 1 |
| Hong Kong | 1 |
| Argentina | 1 |
| Italy | 1 |
| Panama | 1 |
| Taiwan | 1 |
| Sweden | 1 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [Brazilian restaurants in the United States](https://specstream.ai/data/businesses/brazilian-restaurants/united-states)
- [Veterans hospitals in the United States](https://specstream.ai/data/businesses/veterans-hospitals/united-states)
- [Public relations firms in the United States](https://specstream.ai/data/businesses/public-relations-firms/united-states)
- [Logging companies in the United States](https://specstream.ai/data/businesses/logging-companies/united-states)
- [Fire and water damage restoration companies in the United States](https://specstream.ai/data/businesses/fire-and-water-damage-restoration-companies/united-states)
- [Caterers in the United States](https://specstream.ai/data/businesses/caterers/united-states)
